Physician

Peter Daniel Nicholas, D.O.

According to 2025 Medicare claims, Peter Nicholas, D.O. (NPI: 1740714062) practices rheumatology in the Reading, PA market, with the plurality of this provider's patient population coming from Berks, PA. This provider's primary affiliated billing organization is ARTHRITIS AND OSTEOPOROSIS CENTER, INC. (NPI: 1194786491; TIN: 231949591) and primary practice location at 19610-3359.

Nicholas' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 607 traditional Medicare patients, billed 128,399 HCPCS/CPT codes, and received $1,046,100 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,649 prescription claims across 383 beneficiaries totaling $570,914 in drug costs, led by Otezla (Apremilast). Open Payments data shows 74 records totaling $2,127. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $373 to $570,914. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$523K$1.0M2022 Medicare payment: $85,405 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $414,887 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $1,046,100 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
2019N/RN/RN/R
2020N/RN/RN/R
2021N/RN/RN/R
20221435,415$85,405
202334939,891$414,887
2024607128,399$1,046,100

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$285K$571K2017 Drug cost: $373 (USD; Tot_Drug_Cst)2018 Drug cost: $1,016 (USD; Tot_Drug_Cst)2020 Drug cost: $14,048 (USD; Tot_Drug_Cst)2021 Drug cost: $52,286 (USD; Tot_Drug_Cst)2022 Drug cost: $92,337 (USD; Tot_Drug_Cst)2023 Drug cost: $441,981 (USD; Tot_Drug_Cst)2024 Drug cost: $570,914 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015N/RN/RN/R
2016N/RN/RN/R
2017N/R14$373
20181421$1,016
2019N/RN/RN/R
202037115$14,048
202188462$52,286
2022163527$92,337
20232931,272$441,981
20243831,649$570,914

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99205New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more128128$162
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more311526$87
G2211Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's286382$12
96372Injection of drug or substance under skin or into muscle156496$10
J3301Injection, triamcinolone acetonide, not otherwise specified, 10 mg1261,143$1

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
OtezlaApremilast17510$80,890
Hydroxychloroquine SulfateHydroxychloroquine Sulfate1128,371$4,847
MethotrexateMethotrexate Sodium1068,178$4,582
GabapentinGabapentin1156,715$2,700
PrednisonePrednisone23910,087$1,966

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.74$2,127AstraZeneca Pharmaceuticals LP
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Peter Daniel Nicholas, D.O.?

Tedicare shows public-source Medicare data for Peter Daniel Nicholas, D.O. (NPI 1740714062), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Peter Daniel Nicholas, D.O. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Peter Daniel Nicholas, D.O.?

Peter Daniel Nicholas, D.O. is linked to ARTHRITIS AND OSTEOPOROSIS CENTER, INC. (billing NPI 1194786491) in the available physician profile data.

Does Peter Daniel Nicholas, D.O. have Open Payments data?

Peter Daniel Nicholas, D.O. has 74 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.